166 related articles for article (PubMed ID: 15816627)
1. Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
Fujiwara K; Kiura K; Gemba K; Ogata Y; Hotta K; Kishino D; Tabata M; Ueoka H; Tanimoto M
Anticancer Res; 2005; 25(1B):547-9. PubMed ID: 15816627
[TBL] [Abstract][Full Text] [Related]
2. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
6. Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
Stahel R; Rossi A; Petruzelka L; Kosimidis P; de Braud F; Bernardo MM; Souquet PJ; Parra HS; Gridelli C
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S19-23. PubMed ID: 14661049
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
8. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
9. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste J
Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Segawa Y; Hotta K; Umemura S; Fujiwara Y; Shinkai T; Ueoka H; Takigawa N; Tabata M; Kiura K; Tanimoto M
Cancer; 2006 Oct; 107(8):1866-72. PubMed ID: 16967452
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
16. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Kakiuchi S; Daigo Y; Ishikawa N; Furukawa C; Tsunoda T; Yano S; Nakagawa K; Tsuruo T; Kohno N; Fukuoka M; Sone S; Nakamura Y
Hum Mol Genet; 2004 Dec; 13(24):3029-43. PubMed ID: 15496427
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Stinchcombe TE; Socinski MA
Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Reck M; Gatzemeier U
Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Shah NT; Miller VA
Clin Lung Cancer; 2003 Nov; 5(3):182-6. PubMed ID: 14667275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
